Pharmacokinetics of three oral formulations of ciprofloxacin
- PMID: 2931047
- PMCID: PMC176313
- DOI: 10.1128/AAC.28.1.74
Pharmacokinetics of three oral formulations of ciprofloxacin
Abstract
We compared the absorption of three formulations of ciprofloxacin after oral administration in 18 normal adult male volunteers. Each subject received 500 mg of ciprofloxacin as two 250-mg tablets, one 500-mg tablet, or a solution in a randomized crossover sequence. Pharmacokinetic parameters were determined by model independent methods. Because a solution is considered to be the ideal oral dosage form, the results determined for the tablets were compared to those for the solution. Mean values for the maximum concentration of drug in serum, the time to maximum concentration of drug in serum, and the elimination half-life were 3.23 micrograms/ml, 1.00 h, and 5.04 h, respectively, for the solution. The mean renal clearance of ciprofloxacin was 372 ml/min and accounted for at least 50% of the total clearance. We recovered 44.4, 48.6, and 55.8% of the administered ciprofloxacin from the urine as unchanged drug within 24 h after dosing with the 250-mg tablets, 500-mg tablets, or solution, respectively. The 500-mg tablets were found to be bioequivalent to the solution with regard to all pharmacokinetic parameters. The 250-mg tablet was not bioequivalent to either of the other formulations; the relative bioavailability values were 78.7 and 74.1%, respectively, for the 500-mg tablet and the solution. The clinical significance of this difference in bioavailability is yet to be determined.
Similar articles
-
Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers.Antimicrob Agents Chemother. 1984 Nov;26(5):741-4. doi: 10.1128/AAC.26.5.741. Antimicrob Agents Chemother. 1984. PMID: 6517556 Free PMC article.
-
Ciprofloxacin pharmacokinetics and oral absorption of generic ciprofloxacin tablets in dogs.Am J Vet Res. 2012 Jul;73(7):1085-91. doi: 10.2460/ajvr.73.7.1085. Am J Vet Res. 2012. PMID: 22738062
-
A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.Clin Ther. 2009 Sep;31(9):2002-11. doi: 10.1016/j.clinthera.2009.09.016. Clin Ther. 2009. PMID: 19843490 Clinical Trial.
-
Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers.Eur J Clin Microbiol. 1984 Aug;3(4):355-9. doi: 10.1007/BF01977494. Eur J Clin Microbiol. 1984. PMID: 6489326 Clinical Trial.
-
Pharmacokinetics of ciprofloxacin in cystic fibrosis.Antimicrob Agents Chemother. 1987 Jun;31(6):915-9. doi: 10.1128/AAC.31.6.915. Antimicrob Agents Chemother. 1987. PMID: 3619423 Free PMC article. Clinical Trial.
Cited by
-
4-Quinolone drugs affect cell cycle progression and function of human lymphocytes in vitro.Antimicrob Agents Chemother. 1987 May;31(5):768-73. doi: 10.1128/AAC.31.5.768. Antimicrob Agents Chemother. 1987. PMID: 3606076 Free PMC article.
-
Randomized, double-blind comparison of ciprofloxacin and trimethoprim-sulfamethoxazole for complicated urinary tract infections.Antimicrob Agents Chemother. 1988 Sep;32(9):1327-30. doi: 10.1128/AAC.32.9.1327. Antimicrob Agents Chemother. 1988. PMID: 3195995 Free PMC article. Clinical Trial.
-
Comparative evaluation of ciprofloxacin, enoxacin, and ofloxacin in experimental Pseudomonas aeruginosa pneumonia.Antimicrob Agents Chemother. 1986 Mar;29(3):395-9. doi: 10.1128/AAC.29.3.395. Antimicrob Agents Chemother. 1986. PMID: 2940970 Free PMC article.
-
Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group.Ann Surg. 1996 Mar;223(3):303-15. doi: 10.1097/00000658-199603000-00012. Ann Surg. 1996. PMID: 8604912 Free PMC article. Clinical Trial.
-
Clinical pharmacokinetics of the newer antibacterial 4-quinolones.Clin Pharmacokinet. 1988 Feb;14(2):96-121. doi: 10.2165/00003088-198814020-00003. Clin Pharmacokinet. 1988. PMID: 3282749 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources